News from the Anastasia Khvorova Lab at UMass Chan Medical School

Technology developed at UMass Chan Medical School has been licensed by PLaN Therapeutics, a nonprofit biotechnology company owned by the PLN Foundation.

UMass Chan Medical licenses exNA oligonucleotide technology to Hongene Biotech Corporation

The Morningside Graduate School of Biomedical Sciences at UMass Chan Medical School honored student scientists for outstanding research and leadership qualities on May 29.

A siRNA therapeutic for dermatological diseases developed at UMass Chan Medical School has entered the clinical trial phase.

Anastasia Khvorova, PhD, has been awarded the 2025 Else Kröner Fresenius Prize for Medical Research.

A biochemical breakthrough using simple carbon atoms by Ken Yamada, PhD, and Anastasia Khvorova, PhD, has dramatically improved the stability and efficacy of a potential oligonucleotide therapeutic platform in mice.

Natick resident and Stanford Online High School student Rebecca Ahn outperformed other local high school students in the final round of the competition on March 16.

Representatives from UMass Chan presented on several topics and career paths, including RNA Therapeutics Institute, ScienceLive, community and government relations, diversity and inclusion and media and arts in sciences.

A new RNA therapeutic for preeclampsia is based on work by UMass Chan researchers and collaborating scientists. Researchers explain the importance of a multipronged approach to addressing factors underlying health disparities in this Science for Living article.

MD/PhD student Jillian Belgrad has received an award from the National Institute of Neurological Disorders and Stroke to study the pathology that drives the development of Huntington’s disease symptoms.